TransMedics Group, Inc. (BMV:TMDX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 45.36B -36.0% |
| Revenue (ttm) | 11.68B +25.8% |
| Net Income | 2.65B +111.7% |
| EPS | 70.15 +98.9% |
| Shares Out | n/a |
| PE Ratio | 17.11 |
| Forward PE | 35.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31 |
| Open | 1,336.00 |
| Previous Close | 1,405.00 |
| Day's Range | 1,302.00 - 1,336.00 |
| 52-Week Range | 1,050.00 - 2,662.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 30, 2026 |
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial numbers in USD Financial StatementsNews
TransMedics price target lowered to $94 from $95 at Canaccord
Canaccord lowered the firm’s price target on TransMedics (TMDX) to $94 from $95 and keeps a Buy rating on the shares. The firm raised its Q3 earnings estimates ahead of…
TransMedics initiated with an Overweight at Barclays
Barclays initiated coverage of TransMedics (TMDX) with an Overweight rating and $120 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible f...
TransMedics Group Transcript: 2026 Global Healthcare Conference
The company highlighted robust growth, advanced technology, and a vertically integrated service model, with major expansion plans in heart, lung, and kidney transplants, and a strategic push into Europe. Long-term financial targets remain unchanged, and 2027 is expected to be a pivotal growth year.
TransMedics Group Slides: FY 2026
TransMedics Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 15, 2026.
TransMedics Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted ambitious growth targets, with plans to double U.S. NOP cases by 2030, expand internationally, and launch new organ programs, especially kidney. Investments in logistics, automation, and clinical innovation are expected to drive both market share and overall transplant volume growth.
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
TransMedics appoints Fernando Araujo as CFO
TransMedics (TMDX) appointed Fernando Araujo as CFO, effective September 21. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M. He succee...
TransMedics backs 2026 revenue view $737M-$757M, consensus $741.71M
16:09 EDT TransMedics (TMDX) backs 2026 revenue view $737M-$757M, consensus $741.71M
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announce...
TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group Transcript: Canaccord Genuity's 46th Annual Growth Conference
Presented a robust, vertically integrated organ transplant platform with strong financial growth, four major expansion initiatives, and a clear path to $2–$3 billion in revenue. Strategic investments in technology, logistics, and new markets are expected to drive continued margin improvement and industry leadership.
TransMedics Group Slides: Canaccord Genuity's 46th Annual Growth Conference
TransMedics Group has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
TransMedics price target lowered to $77 from $80 at UBS
UBS lowered the firm’s price target on TransMedics (TMDX) to $77 from $80 and keeps a Neutral rating on the shares.
TransMedics price target raised to $122 from $120 at Baird
Baird raised the firm’s price target on TransMedics (TMDX) to $122 from $120 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q2 results…
TransMedics price target lowered to $100 from $120 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on TransMedics (TMDX) to $100 from $120 and keeps an Overweight rating on the shares. The firm notes the company…
TransMedics price target lowered to $95 from $124 at Canaccord
Canaccord lowered the firm’s price target on TransMedics (TMDX) to $95 from $124 and keeps a Buy rating on the shares. The firm said they reported a Q2 revenue beat…
TransMedics price target lowered to $65 from $80 at Stifel
Stifel lowered the firm’s price target on TransMedics (TMDX) to $65 from $80 and keeps a Hold rating on the shares.
TransMedics Group Earnings Call Transcript: Q2 2026
Record Q2 revenue of $190M was driven by strong growth in OCS case volume, clinical services, and logistics, with service revenue outpacing product revenue. Raised 2026 revenue guidance to $737–$757M, excluding PAD Aviation, and expect continued investment in growth initiatives and international expansion.
TransMedics Group Earnings release: Q2 2026
TransMedics Group released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
TransMedics Group Quarterly report: Q2 2026
TransMedics Group has published its Q2 2026 quarterly earnings report on August 4, 2026.
TransMedics Group Slides: Q2 2026
TransMedics Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
TransMedics reports Q2 adjusted EPS 44c, consensus 48c
Reports Q2 revenue $189.9M, consensus $183.99M. “The second quarter was a defining one for TransMedics (TMDX): record revenue, accelerating service growth, and sequential gross margin expansion, all a...
TransMedics Reports Second Quarter 2026 Financial Results
ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...